Platelet to lymphocyte ratio (PLR) is a candidate prognostic marker for metastatic castration-resistant prostate cancer patients receiving abiraterone acetate and evidence demonstrates that a high PLR is associated with poor survival. More studies are required to verify current findings and establish a definite cutoff point.
Keywords: abiraterone; lymphocyte; metastatic Castration‐Resistant Prostate Cancer; platelet; platelet to lymphocyte ratio; prostate cancer.